YKL-40 as a new promising prognostic marker of severity in COVID infection.

Aged; Aged, 80 and over; Biomarkers/blood; COVID-19/blood/therapy; Chitinase-3-Like Protein 1/blood; Female; Humans; Intensive Care Units/statistics & numerical data; Male; Middle Aged; Patient Admission/statistics & numerical data; Prognosis; Retrospective Studies; Severity of Illness Index; COVID-19; Chitinase 3-like 1; Interstitial lung disease; SARS-CoV-2; YKL-40

Disciplines :

Laboratory medicine & medical technology
General & internal medicine

Author, co-author :

Schoneveld, Lauranne ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Pool assistant - biologie clinique

LADANG, Aurélie ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire endocrinologie

HENKET, Monique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de l'asthme

Frix, Anne-Noëlle ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie

Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale

Guiot, Julien ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie

Other collaborator :

MALAISE, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie

LAMBERMONT, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine - Pool assistants

Language :

English

Title :

YKL-40 as a new promising prognostic marker of severity in COVID infection.

Publication date :

February 2021

Journal title :

Critical Care

ISSN :

1364-8535

eISSN :

1466-609X

Volume :

Issue :

Pages :

Peer reviewed :

Peer reviewed

Available on ORBi :

since 26 February 2021

Statistics

Number of views

218 (18 by ULiège)

Number of downloads

10 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Korthagen NM, van Moorsel CHM, Barlo NP, Ruven HJT, Kruit A, Heron M, et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med. 2011;105:106–13. DOI: 10.1016/j.rmed.2010.09.012
Létuvé S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret M-C, et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol. 2008;181:5167–73. DOI: 10.4049/jimmunol.181.7.5167
Nordenbæk C, Johansen JS, Halberg P, Wiik A, Garbarsch C, Ullman S, et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol. 2005;34:293–7. DOI: 10.1080/03009740510018598
Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 2020;158:646–59. DOI: 10.1016/j.chest.2020.03.037
Guiot J, Moermans C, Henket M, Corhay JL, Louis R. Blood biomarkers in idiopathic pulmonary fibrosis. Lung. 2017;195:273–80. DOI: 10.1007/s00408-017-9993-5
Bonhomme O, André B, Gester F, De Seny D, Moermans C, Struman I, et al. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatol (United Kingdom). 2019;58:1534–46.